Anuh Pharma Reports FY26 Results

Anuh Pharma's revenue for the year ended March 31, 2026, reached ₹77,601.30 Lakhs. This marks a 15.66% increase from the previous year's ₹67,097.02 Lakhs. However, profit after tax for the full year saw a 13.32% decline, falling to ₹4,104.61 Lakhs from ₹4,735.19 Lakhs.

For the fourth quarter of FY26, total revenue was ₹20,086.26 Lakhs, a marginal 0.66% increase compared to ₹19,953.78 Lakhs in the same period last year. Profit after tax for the quarter decreased by 6.23% to ₹1,168.14 Lakhs from ₹1,245.70 Lakhs in the prior year.

Key Financial Highlights

Anuh Pharma announced its financial results for the fiscal year and fourth quarter ending March 31, 2026. The company achieved annual revenue growth of 15.66%, but annual profit after tax decreased by 13.32%. Quarterly revenue saw a slight increase of 0.66%, while profit after tax declined by 6.23%. Additionally, the company reported eliminating its current borrowings and recommended a final dividend.

Why Profitability Declined

While the revenue growth indicates business expansion, the dip in profitability, both annually and quarterly, points to potential margin pressures. Rising expenses that outpaced revenue growth are cited as a contributing factor. Investors are likely looking for explanations on the reasons behind the profit decrease and the company's strategy to improve margins.

Financial Strength and Shareholder Returns

The company has strengthened its balance sheet by reducing current borrowings to nil from ₹1,049.81 Lakhs in the previous fiscal year. The recommended dividend and a past bonus share issue signal a focus on shareholder returns. However, the declining profit margins remain a key area for management to address for sustainable growth.

Potential Risks to Monitor

Beyond margin pressure from rising expenses, Anuh Pharma faces other potential risks. These include a quarterly mark-to-market loss on investments and a possible increase in gratuity and leave liabilities stemming from new Labour Codes. These factors could impact future financial performance.

Financial Metrics

• Annual Revenue FY26: ₹77,601.30 Lakhs (vs ₹67,097.02 Lakhs FY25)
• Annual Profit After Tax FY26: ₹4,104.61 Lakhs (vs ₹4,735.19 Lakhs FY25)
• Quarterly Revenue Q4 FY26: ₹20,086.26 Lakhs (vs ₹19,953.78 Lakhs Q4 FY25)
• Quarterly Profit After Tax Q4 FY26: ₹1,168.14 Lakhs (vs ₹1,245.70 Lakhs Q4 FY25)
• Current Borrowings: ₹0 (vs ₹1,049.81 Lakhs previously)
• Equity: ₹35,222.24 Lakhs (vs ₹32,602.48 Lakhs previously)

What Investors Should Watch

Investors will be closely monitoring Anuh Pharma's upcoming quarters for signs of improved profit margins and effective control over operating expenses. Management's commentary on strategies to tackle profitability challenges and adapt to the impact of new Labour Codes will be crucial for assessing future performance.